価格表

在庫・価格 : 2024年03月28日 22時22分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-PD-L1, Rabbit-Poly <Anti-CD274>
データシート
GTX104763 GNTジーンテックス
GeneTex International Corporation
25 μl ¥23,000 1個 追加

在庫・価格 : 2024年03月28日 22時22分 現在

Anti-PD-L1, Rabbit-Poly <Anti-CD274>

  • 商品コード:GTX104763
  • メーカー:GNT
  • 包装:25μl
  • 価格: ¥23,000
  • 在庫:1個
使用文献
No. 文献情報 備考 参照
1 Lin YM et al. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS ONE 2015;10(11):e0142656
Lin YM et al
2015/01/01
PubMed
2 Qing Y et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther 2015;9:901-9
Qing Y et al
2015/01/01
PubMed
3 Wang LT et al. Intestine-Specific Homeobox Gene <i>ISX</i> Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression. Cancer Res. 2017 08;77(15):4065-4077
Wang LT et al
2017/01/01
Application: Western blot, Reactivity: Human PubMed
4 Lin PL et al. A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers. Cancer Med 2017 Sep;6(9):2052-2062
Lin PL et al
2017/01/01
Application: IHC (Formalin-fixed paraffin-embedded sections), Reactivity: Human PubMed
5 Lin PL et al. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling. Eur. J. Cancer 2017 11;85:95-105
Lin PL et al
2017/01/01
Application: IHC (Formalin-fixed paraffin-embedded sections), Reactivity: Human PubMed
6 He B et al. Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1. Biomed. Pharmacother. 2018 Feb;98:95-101
He B et al
2018/01/01
Application: Western Blot (WB), Reactivity: Human PubMed
7 Li CW et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell 2018 Feb;33(2):187-201.e10
Li CW et al
2018/01/01
Application: Western Blot (WB), Reactivity: Human PubMed
8 Takeuchi M et al. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunol. Lett. 2018 Apr;196:155-160
Takeuchi M et al
2018/01/01
Application: Western Blot (WB), Reactivity: Human PubMed
9 Cha JH et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol. Cell 2018 Aug;71(4):606-620.e7
Cha JH et al
2018/01/01
Application: IHC (Frozen sections), Reactivity: Human PubMed
10 Buisseret L et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology 2017;6(1):e1257452
Buisseret L et al
2017/01/01
PubMed
11 Polioudaki H et al. Nuclear localization of PD-L1: artifact or reality? Cell Oncol (Dordr) 2019 Apr;42(2):237-242
Polioudaki H et al
2019/01/01
Application: Western Blot, Reactivity: Human PubMed
12 Kim D et al. Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder. J Clin Med 2020 Apr;9(5)
Kim D et al
2020/01/01
PubMed
13 Lenouvel D et al. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. Oral Oncol. 2020 07;106:104722
Lenouvel D et al
2020/01/01
PubMed
14 Gondhowiardjo SA et al. Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer. PLoS ONE 2020;15(3):e0230449
Gondhowiardjo SA et al
2020/01/01
PubMed
15 Pan MR et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers (Basel) 2019 Dec;12(1)
Pan MR et al
2019/01/01
PubMed
16 Chan LC et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J. Clin. Invest. 2019 07;129(8):3324-3338
Chan LC et al
2019/01/01
PubMed
17 Li L et al. Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer. Cancer Sci 2021 May;112(5):1772-1784
Li L et al
2021/01/01
PubMed
18 Qin G et al. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. Nat Commun 2020 04;11(1):1669
Qin G et al
2020/01/01
PubMed
19 Chou CW et al. The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. Am J Cancer Res 2020;10(8):2621-2634
Chou CW et al
2020/01/01
PubMed
20 Huang TY et al. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer. Cells 2020 08;9(8)
Huang TY et al
2020/01/01
PubMed
21 Nguyen HD et al. The &#x3B1;9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration. Cancers (Basel) 2019 Dec;11(12)
Nguyen HD et al
2019/01/01
PubMed
22 Wei-faYang et al., Wei-faYang, Oral Oncology, 2018

PubMed
23 Liu Z et al. Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis. Int J Clin Exp Pathol 2017;10(12):11754-11759
Liu Z et al
2017/01/01
PubMed
24 Liu Z et al., Liu Z, lInt J Clin Exp Pathol, 2017

PubMed
25 Buisseret L et al., Buisseret L, OncoImmunology, 2016

PubMed
26 Tuminello S et al. PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 2020 Aug;9(4):1343-1360
Tuminello S et al
2020/01/01
PubMed
27 Omenai SA et al. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients. PLoS One 2022;17(2):e0263615
Omenai SA et al
2022/01/01
PubMed
28 Asrini R et al. Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Mol Clin Oncol 2022 Feb;16(2):42
Asrini R et al
2022/01/01
PubMed
29 Lin YZ, et al., miR-4759 suppresses breast cancer through immune checkpoint blockade., Computational and Structural Biotechnology Journal., 2022

PubMed
30 Li L, et al., A combination therapy of ingredients from TCM for the prevention and treatment of gastric cancer by targeting HER2/ PD-L1., Pharmacological Research - Modern Chinese Medicine., 2021

PubMed
31 Hung YH et al. Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1. Am J Cancer Res 2022;12(2):713-728
Hung YH et al
2022/01/01
PubMed
32 Pacheco-Torres J et al. The PD-L1 metabolic interactome intersects with choline metabolism and inflammation. Cancer Metab 2021 Feb;9(1):10
Pacheco-Torres J et al
2021/01/01
PubMed
33 Lin YZ et al. miR-4759 suppresses breast cancer through immune checkpoint blockade. Comput Struct Biotechnol J 2022;20:241-251
Lin YZ et al
2022/01/01
PubMed
  • No.: 1
  • 文献情報:
    Lin YM et al. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS ONE 2015;10(11):e0142656
    Lin YM et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Qing Y et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther 2015;9:901-9
    Qing Y et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Wang LT et al. Intestine-Specific Homeobox Gene <i>ISX</i> Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression. Cancer Res. 2017 08;77(15):4065-4077
    Wang LT et al
    2017/01/01
  • 備考:
    Application: Western blot, Reactivity: Human
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Lin PL et al. A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers. Cancer Med 2017 Sep;6(9):2052-2062
    Lin PL et al
    2017/01/01
  • 備考:
    Application: IHC (Formalin-fixed paraffin-embedded sections), Reactivity: Human
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Lin PL et al. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling. Eur. J. Cancer 2017 11;85:95-105
    Lin PL et al
    2017/01/01
  • 備考:
    Application: IHC (Formalin-fixed paraffin-embedded sections), Reactivity: Human
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    He B et al. Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1. Biomed. Pharmacother. 2018 Feb;98:95-101
    He B et al
    2018/01/01
  • 備考:
    Application: Western Blot (WB), Reactivity: Human
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Li CW et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell 2018 Feb;33(2):187-201.e10
    Li CW et al
    2018/01/01
  • 備考:
    Application: Western Blot (WB), Reactivity: Human
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Takeuchi M et al. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunol. Lett. 2018 Apr;196:155-160
    Takeuchi M et al
    2018/01/01
  • 備考:
    Application: Western Blot (WB), Reactivity: Human
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Cha JH et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol. Cell 2018 Aug;71(4):606-620.e7
    Cha JH et al
    2018/01/01
  • 備考:
    Application: IHC (Frozen sections), Reactivity: Human
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Buisseret L et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology 2017;6(1):e1257452
    Buisseret L et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Polioudaki H et al. Nuclear localization of PD-L1: artifact or reality? Cell Oncol (Dordr) 2019 Apr;42(2):237-242
    Polioudaki H et al
    2019/01/01
  • 備考:
    Application: Western Blot, Reactivity: Human
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Kim D et al. Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder. J Clin Med 2020 Apr;9(5)
    Kim D et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Lenouvel D et al. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. Oral Oncol. 2020 07;106:104722
    Lenouvel D et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Gondhowiardjo SA et al. Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer. PLoS ONE 2020;15(3):e0230449
    Gondhowiardjo SA et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Pan MR et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers (Basel) 2019 Dec;12(1)
    Pan MR et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Chan LC et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J. Clin. Invest. 2019 07;129(8):3324-3338
    Chan LC et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Li L et al. Systematic insight into the active constituents and mechanism of Guiqi Baizhu for the treatment of gastric cancer. Cancer Sci 2021 May;112(5):1772-1784
    Li L et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Qin G et al. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. Nat Commun 2020 04;11(1):1669
    Qin G et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Chou CW et al. The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. Am J Cancer Res 2020;10(8):2621-2634
    Chou CW et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Huang TY et al. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer. Cells 2020 08;9(8)
    Huang TY et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Nguyen HD et al. The &#x3B1;9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration. Cancers (Basel) 2019 Dec;11(12)
    Nguyen HD et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Wei-faYang et al., Wei-faYang, Oral Oncology, 2018

  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Liu Z et al. Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis. Int J Clin Exp Pathol 2017;10(12):11754-11759
    Liu Z et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Liu Z et al., Liu Z, lInt J Clin Exp Pathol, 2017

  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Buisseret L et al., Buisseret L, OncoImmunology, 2016

  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Tuminello S et al. PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 2020 Aug;9(4):1343-1360
    Tuminello S et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Omenai SA et al. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients. PLoS One 2022;17(2):e0263615
    Omenai SA et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Asrini R et al. Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Mol Clin Oncol 2022 Feb;16(2):42
    Asrini R et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Lin YZ, et al., miR-4759 suppresses breast cancer through immune checkpoint blockade., Computational and Structural Biotechnology Journal., 2022

  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Li L, et al., A combination therapy of ingredients from TCM for the prevention and treatment of gastric cancer by targeting HER2/ PD-L1., Pharmacological Research - Modern Chinese Medicine., 2021

  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Hung YH et al. Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1. Am J Cancer Res 2022;12(2):713-728
    Hung YH et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Pacheco-Torres J et al. The PD-L1 metabolic interactome intersects with choline metabolism and inflammation. Cancer Metab 2021 Feb;9(1):10
    Pacheco-Torres J et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Lin YZ et al. miR-4759 suppresses breast cancer through immune checkpoint blockade. Comput Struct Biotechnol J 2022;20:241-251
    Lin YZ et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed